Prehospital ticagrelor in ST-segment elevation myocardial infarction
New England Journal of Medicine, Volume 371, No. 11, Year 2014
Notification
URL copied to clipboard!
BACKGROUND The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown.